CS275231B2 - Medicine bottle - Google Patents
Medicine bottleInfo
- Publication number
- CS275231B2 CS275231B2 CS895552A CS555289A CS275231B2 CS 275231 B2 CS275231 B2 CS 275231B2 CS 895552 A CS895552 A CS 895552A CS 555289 A CS555289 A CS 555289A CS 275231 B2 CS275231 B2 CS 275231B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- per
- ointment base
- antiphlogistics
- medicine bottle
- medcamentous
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000003883 ointment base Substances 0.000 abstract 2
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 abstract 1
- 108010039627 Aprotinin Proteins 0.000 abstract 1
- 108010001478 Bacitracin Proteins 0.000 abstract 1
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 229930193140 Neomycin Natural products 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229960004405 aprotinin Drugs 0.000 abstract 1
- 229960003071 bacitracin Drugs 0.000 abstract 1
- 229930184125 bacitracin Natural products 0.000 abstract 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229960005091 chloramphenicol Drugs 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 229940124448 dermatologic drug Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 108010039262 elastatinal Proteins 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 1
- 229960004927 neomycin Drugs 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Centrifugal Separators (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS895552A CS275231B2 (en) | 1989-09-29 | 1989-09-29 | Medicine bottle |
| CA002026166A CA2026166A1 (en) | 1989-09-29 | 1990-09-25 | Medicamentous form |
| DE69030476T DE69030476T2 (de) | 1989-09-29 | 1990-09-26 | Verwendung von Protease-Inhibitoren als antiexudative, antiphlogistische und antimikrobielle Mittel |
| US07/588,322 US5244673A (en) | 1989-09-29 | 1990-09-26 | Medicamentous form for use as an ophthalmologic, otolaryngologic, or dermatologic drug |
| AU63170/90A AU6317090A (en) | 1989-09-29 | 1990-09-26 | Medicamentous form |
| AT90310516T ATE151640T1 (de) | 1989-09-29 | 1990-09-26 | Verwendung von protease-inhibitoren als antiexudative, antiphlogistische und antimikrobielle mittel |
| EP90310516A EP0420600B1 (en) | 1989-09-29 | 1990-09-26 | Use of protease inhibitors as antiexudative, antiphlogistic and antimicrobial agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS895552A CS275231B2 (en) | 1989-09-29 | 1989-09-29 | Medicine bottle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS275231B2 true CS275231B2 (en) | 1992-02-19 |
Family
ID=5400638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS895552A CS275231B2 (en) | 1989-09-29 | 1989-09-29 | Medicine bottle |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5244673A (cs) |
| EP (1) | EP0420600B1 (cs) |
| AT (1) | ATE151640T1 (cs) |
| AU (1) | AU6317090A (cs) |
| CA (1) | CA2026166A1 (cs) |
| CS (1) | CS275231B2 (cs) |
| DE (1) | DE69030476T2 (cs) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2054180C1 (ru) * | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| EP0532465B1 (de) * | 1991-09-13 | 2002-07-10 | Pentapharm A.G. | Proteinfraktion zur kosmetischen und dermatologischen Pflege der Haut |
| FI920206A0 (fi) * | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| GB2271507A (en) * | 1992-09-04 | 1994-04-20 | Summit Technology Ireland Bv | Compositions containing plasmin activity inhibitors |
| IL109705A (en) * | 1993-06-17 | 1998-07-15 | Allergan Inc | Enzyme compositions and methods for contact lens cleaning |
| US5783532A (en) * | 1993-06-17 | 1998-07-21 | Allergan | Enzyme compositions and methods for contact lens cleaning |
| AU7928294A (en) * | 1993-10-06 | 1995-05-01 | Allergan, Inc. | Compositions and methods for inhibiting and reducing lysozyme deposition on hydrophilic contact lenses |
| US5688781A (en) * | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
| GB2318732A (en) | 1996-11-01 | 1998-05-06 | Johnson & Johnson Medical | Wound healing compositions containing alpha-1-antitrypsin |
| ES2284202T3 (es) * | 1997-05-14 | 2007-11-01 | Senju Pharmaceutical Co., Ltd. | Preparaciones acuosas en suspension con excelente redispersabilidad. |
| EP1124558A4 (en) * | 1998-09-28 | 2004-10-27 | Res Foundation Ofstate Univers | NEW CATARACT TRAINING INHIBITOR |
| US6914057B1 (en) | 1998-09-28 | 2005-07-05 | The Research Foundation Of State University Of New York | Inhibitor of cataract formation |
| IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
| KR100450864B1 (ko) * | 2001-11-23 | 2004-10-01 | 한국과학기술연구원 | Ｒｎａ 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법 |
| DE10227938B4 (de) * | 2002-06-21 | 2006-07-20 | Heraeus Kulzer Gmbh | Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung |
| ES2330516T3 (es) * | 2002-11-20 | 2009-12-11 | Prometic Biosciences Inc. | Composicion para el tratamiento de la ictiosis que utiliza la antitripsina. |
| US20050261243A1 (en) * | 2004-04-21 | 2005-11-24 | Peyman Gholam A | Antiprostaglandins for the treatment of ocular pathologies |
| WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
| US20080038338A1 (en) * | 2006-06-15 | 2008-02-14 | Smith Alexander D | Tetracycline Package Formulations |
| FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| US9290754B2 (en) | 2014-04-17 | 2016-03-22 | Synthetic Biologics Inc. | Beta-lactamases with improved properties for therapy |
| WO2016033327A1 (en) | 2014-08-28 | 2016-03-03 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
| US10105322B2 (en) | 2014-10-08 | 2018-10-23 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
| EP3236993B1 (en) | 2014-12-23 | 2023-09-13 | Theriva Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| EP3261662B1 (en) | 2015-02-23 | 2021-07-21 | Synthetic Biologics Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
| AU2016229976B2 (en) | 2015-03-06 | 2021-11-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
| WO2017146603A1 (en) * | 2016-02-24 | 2017-08-31 | Arcasiu Nicolae | Pharmaceutical composition for the treatment of burns, use, and method of treatment |
| WO2018075810A1 (en) * | 2016-10-18 | 2018-04-26 | Somahultion, Llc | Dermatological compositions for providing nutrients to skin and methods thereof |
| US10328154B2 (en) * | 2017-10-27 | 2019-06-25 | BUFFERAD Illinois Inc. | Topical compositions for improved delivery of active agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU469815B2 (en) * | 1971-04-14 | 1973-10-18 | Anti-inflammatory compositions | |
| SE375007B (cs) * | 1972-11-30 | 1975-04-07 | Pharmacia Ab | |
| FI854634A0 (fi) * | 1985-11-22 | 1985-11-22 | Labsystems Oy | Foerfarande foer bestaemning av proteolytisk aktivitet. |
-
1989
- 1989-09-29 CS CS895552A patent/CS275231B2/cs not_active IP Right Cessation
-
1990
- 1990-09-25 CA CA002026166A patent/CA2026166A1/en not_active Abandoned
- 1990-09-26 AU AU63170/90A patent/AU6317090A/en not_active Abandoned
- 1990-09-26 DE DE69030476T patent/DE69030476T2/de not_active Expired - Fee Related
- 1990-09-26 EP EP90310516A patent/EP0420600B1/en not_active Expired - Lifetime
- 1990-09-26 AT AT90310516T patent/ATE151640T1/de not_active IP Right Cessation
- 1990-09-26 US US07/588,322 patent/US5244673A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU6317090A (en) | 1991-04-11 |
| DE69030476T2 (de) | 1997-11-27 |
| EP0420600B1 (en) | 1997-04-16 |
| DE69030476D1 (de) | 1997-05-22 |
| EP0420600A3 (en) | 1992-11-19 |
| EP0420600A2 (en) | 1991-04-03 |
| US5244673A (en) | 1993-09-14 |
| CA2026166A1 (en) | 1991-03-30 |
| ATE151640T1 (de) | 1997-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS275231B2 (en) | Medicine bottle | |
| TW234691B (cs) | ||
| TW337488B (en) | A carbohydrate glass matrix for the sustained release of a therapeutic agent | |
| GR3034921T3 (en) | Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer. | |
| AU5094985A (en) | Wound healing agents | |
| AU3351293A (en) | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | |
| GB2276819B (en) | Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol | |
| AU3382995A (en) | Combined preparation for the therapy of immunological diseases | |
| PL264392A1 (en) | A microbes killing agent | |
| CA2136331A1 (en) | New pharmaceutical uses of krill enzymes | |
| MY106271A (en) | Cyclosporin ophthalmic compositions. | |
| AU2689292A (en) | Cyclohexaneacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | |
| AU5938398A (en) | Pour-on formulations containing polymeric material, glycols and glycerides | |
| GR3033728T3 (en) | Tablets containing thioctic acid with a specified size. | |
| ATE116849T1 (de) | Pharmazeutische verwendung von fettsäuren. | |
| AU1944997A (en) | Angiogenic inhibitor containing tissue factor pathway inhibitor | |
| MY112593A (en) | A storage stable water solution for infusion containing a thrombin inhibitor | |
| CA2067374A1 (en) | Osteogenesis promoter | |
| AU2360592A (en) | Polyacrylic acid based ophthalmic compositions | |
| AU5187493A (en) | Use of certain methanebisphosphonic acid derivatives in fracture healing | |
| PL307051A1 (en) | Ophthalmic agent for local administration containing (s)-thymol semihydrate | |
| AU643696B2 (en) | Use of iodopropargyl esters of a-amino acid derivatives as antimicrobial agents | |
| AU7037591A (en) | Stabilization of t-pa pro | |
| HK8994A (en) | Medicament for treatment of pregnancy-induced hypertension | |
| IL98200A0 (en) | Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20010929 |